Given the striking effects of the TME in promoting tumour progression and chemotherapeutic resistance, we reasoned the efficiency of in vivo targeting of TAK1 by comparing with that of inhibiting mTOR or p38 in chemotherapeutic settings. Here, MTOR is linked to neoplasm.